胃复春片联合化疗治疗晚期非小细胞肺癌的临床观察

目的观察胃复春片联合化疗治疗晚期非小细胞肺癌（NSCLC）的临床疗效及毒副反应。方法68例晚期NSCLC患者随机数字表法分为两组，每组各34例，对照组采用单纯化疗（吉西他滨＋顺铂），观察组采用胃复春片（1．436g／次，2次／d）联合化疗，完成2个周期治疗后进行疗效及毒副反应评价。结果对照组有效率为41．18％（14／34），观察组有效率为52．94％（18／34），两组差异无统计学意义（χ2=0．94，P〉0．05）。但观察组改善生活质量效果明显优于对照组（χ2=4．12，P〈0．05），并且发生血小板、白细胞、血红蛋白减少及恶心呕吐等毒副反应明显低于对照组（χ2=4．66、5．96、4．12、5．90，均P〈0．05）。结论胃复春片联合化疗治疗晚期NSCLC有较好疗效，能有效减轻化疗毒副反应，提高了患者生活质量，值得临床推广。

The effect of Weifuchun tablet combined with chemotherapy on patients with advanced non-small cell lung cancer

Objective To explore the clinical effect of Weifuchun tablet combined with chemotherapy on patients with advanced non-small cell lung cancer （NSCLC）. Methods Sixty-eight patients with advanced NSCLC was randomly divided into control group （ n = 34） treated with cisplatin ＋ gemcitabine and treatment group （ n = 34 ） treated with Weifuehun tablet （ 1. 436g × 2/d） and cisplatin ＋ gemcitabine. After two treatment cycles, the clinical effect in both groups were evaluated. Results The clinical efficacy in the treatment group was 52.94% （18/34） , which in the control group was 41.18%（ 14/34）, there was no statistically significant difference between the two groups （ χ2 = 0.94, P 〉 0.05 ）. The quality of life and the level of T lymphocytes were markedly improved, and the reduction of hemoglobin,leucocyte, and platelet, and nausea reaction were all significantly inhibited in treatment group compared with that in control group after two treatment cycles （ χ2 = 4.12,4.66,5.96,4.12,5.90, all P 〈 0.05 ）. Conclusion Weifuchun tablet combined with chemotherapy effectively ameliorates the clinical symptoms of the patient with advanced NSCLC, reduces the toxic and side effects caused by chemotherapy, and improves the quality of life,which is worthy in the clinic.